Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 19/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16855259 | 0.89 | ADRA1A (0.80) | ADRA1AKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL20220382 | 0.89 | ADRA1A (0.80) | ADRA1AKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL16846280 | 0.86 | ADRA1A (1.00) | ADRA1AKDM4E | |
| SCHEMBL18143544 | 0.83 | ADRA1A (0.86) | ADRA1A | |
| SCHEMBL16846289 | 0.83 | ADRA1A (1.00) | ADRA1A | |
| SCHEMBL16846240 | 0.83 | ADRA1A (1.00) | ADRA1A | |
| SCHEMBL16846263 | 0.82 | ADRA1A (1.00) | ADRA1A | |
| SCHEMBL16846269 | 0.81 | ADRA1A (1.00) | ADRA1A | |
| SCHEMBL18143310 | 0.80 | ADRA1A (0.87) | ADRA1A | |
| SCHEMBL16846281 | 0.80 | ADRA1A (1.00) | ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220016113-A1 | ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2022-01-20 | — | — | US | disclosed |
| EP-3883933-A1 | a2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2021-09-29 | — | — | EP | disclosed |
| US-9624198-B2 | Substituted piperidinyltetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9624198-B2 | Substituted piperidinyltetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9624198-B2 | Substituted piperidinyltetrahydroquinolines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-18 | — | — | US | disclosed |
| US-20160304491-A1 | SUBSTITUTED PIPERIDINYLTETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-20 | — | — | US | disclosed |
| US-20160304491-A1 | SUBSTITUTED PIPERIDINYLTETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-20 | — | — | US | disclosed |
| US-20160304491-A1 | SUBSTITUTED PIPERIDINYLTETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-20 | — | — | US | disclosed |
| WO-2015091417-A1 | SUBSTITUTED PIPERIDINYL-TETRAHYDROQUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016113-A1 | ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, HTR2C | ADRA1A 13/4885KDM4E 3937/4885KMT2A 1565/4885 |
| US-20160304491-A1 | SUBSTITUTED PIPERIDINYLTETRAHYDROQUINOLINES | TNNI3, TNNC1, PRPH | ADRA1A 1949/4885KDM4E 3912/4885KMT2A 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.